| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | A-443654 | GDSC1000 | pan-cancer | AAC | -0.077 | 0.1 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.048 | 0.1 |
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | -0.05 | 0.1 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | 0.044 | 0.1 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | -0.058 | 0.1 |
| mRNA | AG-014699 | GDSC1000 | pan-cancer | AAC | 0.05 | 0.1 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | SNS-032 | CTRPv2 | pan-cancer | AAC | -0.053 | 0.1 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.079 | 0.1 |
| mRNA | piperlongumine:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.052 | 0.1 |